PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Proquest Summons
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Michael Wang
Michael Wang
Unit 429, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
Tanzania
Publications
-
Review Article
Marginal Zone Lymphoma Perge Progredi, Next on the Horizon
Author(s): Hun Ju Lee, Madhav Desai, Liang Zhang, Qingqing Cai, Dehui Zou and Michael WangHun Ju Lee, Madhav Desai, Liang Zhang, Qingqing Cai, Dehui Zou and Michael Wang
Marginal Zone Lymphoma (MZL) is a clonal indolent mature B-cell malignancy. MZL accounts for 10% of all Non-Hodgkin Lymphomas (NHL). The common etiologic hallmarks of MZL are chronic antigenic B-cell stimulation, which leads to increased DNA replication errors and genomic instability. Standard therapy for MZL has been watch and wait, cytotoxic chemotherapy, surgery, and/or radiation therapy based on clinical risk factors. However, novel developments of targeted therapies have brought new excitement to MZL therapeutic armamentarium. In this article, we provide an update on the novel diagnostic approaches to MZL as well as innovative molecular targets that will ultimately become the next therapeutic paradigm for patients with MZL. .. View More»
DOI: 10.4172/2155-9864.1000174